
Personalized mRNA Cancer Vaccine Clears Phase 3 Hurdle
Moderna and Merck reported positive Phase 3 results for personalized mRNA cancer vaccine mRNA-4157 combined with pembrolizumab in high-risk melanoma after surgery. The treatment significantly improved recurrence-free and distant metastasis-free survival versus pembrolizumab alone, though detailed data and overall survival results are still pending.






